Diamedica TherapeuticsDMAC
13F holders, Q4 2024 (December 31)At the end of Q4 2024, 45 institutions reported holding Diamedica Therapeutics Inc. (DMAC) in their 13F filings, up 5 from Q3 2024. 11 opened new positions and 5 sold out. The largest holders were Omega Advisors (Leon Cooperman) ($8.8M), Vanguard Group Inc. ($6.7M) and First Manhattan Co. Llc. ($4.6M). 3 famous investors held it, including Leon Cooperman (0.3% of Omega Advisors (Leon Cooperman)'s portfolio), Israel Englander (0.0% of Millennium Management's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Diamedica Therapeutics Inc.
- CUSIP
- 25253X207
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 11 | $1.9M |
| Exits | 5 | $73K |
All 13F filers, Q3 2024 → Q4 2024: 1,199,733 shares bought and 52,811 shares sold, net +1,146,922 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 45 holders
| Omega Advisors (Leon Cooperman) | 0.33% | Add +7.5% | 1,625,000 | $8.8M |
| Vanguard Group Inc. | 0.00% | Add +18.4% | 1,242,107 | $6.7M |
| First Manhattan Co. Llc. | 0.01% | No change | 839,081 | $4.6M |
| Paragon Associates & Paragon Associates II Joint Venture | 6.46% | Add +6.7% | 514,784 | $2.8M |
| Bleichroeder LP | 0.52% | No change | 382,317 | $2.1M |
| Susquehanna International Group, LLP | 0.00% | Add +269.5% | 374,845 | $2.0M |
| Geode Capital Management, LLC | 0.00% | Reduce -0.4% | 305,751 | $1.7M |
| Northern Trust Corp. | 0.00% | Add +49.8% | 180,192 | $978K |
| LPL Financial LLC | 0.00% | Add +8.2% | 152,000 | $825K |
| BlackRock, Inc. | 0.00% | Add +0.1% | 107,880 | $586K |
| Qube Research & Technologies Ltd | 0.00% | Add +81.9% | 94,769 | $515K |
| Morgan Stanley | 0.00% | Reduce -20.5% | 87,429 | $475K |
| State Street Corp. | 0.00% | Add +23.7% | 85,029 | $462K |
| Millennium Management | 0.00% | Add +151.8% | 84,829 | $461K |
| 683 Capital Management, LLC | 0.05% | New | 76,116 | $413K |
| Blue Trust, Inc. | 0.00% | Add +56.2% | 69,122 | $375K |
| Goldman Sachs Group Inc. | 0.00% | New | 68,948 | $374K |
| Jane Street Group, LLC | 0.00% | New | 42,212 | $229K |
| Citigroup Inc. | 0.00% | Add +74.1% | 38,474 | $209K |
| Catalyst Financial Partners LLC | 0.04% | No change | 38,457 | $209K |
| Barclays PLC | 0.00% | New | 27,726 | $151K |
| Meridian Wealth Management, LLC | 0.01% | New | 27,216 | $148K |
| Schonfeld Strategic Advisors LLC | 0.00% | New | 26,097 | $142K |
| Jefferies Financial Group Inc. | 0.00% | No change | 26,000 | $141K |
| OMERS ADMINISTRATION Corp | 0.00% | New | 22,500 | $122K |
| World Investment Advisors | 0.00% | New | 21,915 | $119K |
| Dimensional Fund Advisors LP | 0.00% | Add +14.0% | 19,339 | $105K |
| Stonebridge Capital Advisors LLC | 0.01% | No change | 17,500 | $95K |
| BNP Paribas Financial Markets | 0.00% | Add +1.8% | 16,800 | $91K |
| Citadel Advisors | 0.00% | Add +36.2% | 16,113 | $87K |
| Bank of Montreal | 0.00% | New | 15,560 | $84K |
| Raymond James Financial Inc. | 0.00% | — | 15,267 | $83K |
| Y-Intercept (Hong Kong) Ltd | 0.01% | New | 14,973 | $81K |
| Balyasny Asset Management L.P. | 0.00% | New | 14,581 | $79K |
| Charles Schwab Investment Management Inc. | 0.00% | No change | 13,251 | $72K |
| Magnolia Capital Advisors LLC | 0.01% | Add +1.6% | 10,160 | $55K |
| MassMutual Private Wealth & Trust, FSB | 0.00% | No change | 4,824 | $26K |
| US Bancorp \de | 0.00% | No change | 4,335 | $24K |
| UBS Group AG | 0.00% | Reduce -86.1% | 1,769 | $10K |
| TD Waterhouse Canada Inc. | 0.00% | No change | 1,070 | $6K |
| Osaic Holdings, Inc. | 0.00% | No change | 1,055 | $6K |
| Legend Financial Advisors, Inc. | 0.00% | No change | 1,000 | $5K |
| Royal Bank of Canada | 0.00% | Reduce -59.0% | 330 | $2K |
| Bank of America Corp. | 0.00% | Reduce -1.9% | 209 | $1K |
| Cornerstone Planning Group LLC | 0.00% | No change | 80 | $485 |
"% of holder's portfolio" is DMAC's weight in each manager's 13F, not the share of Diamedica Therapeutics Inc. the manager owns.